What kisspeptin is
Kisspeptins are peptides produced from the KISS1 gene that activate the KISS1 receptor upstream of gonadotropin-releasing hormone. Kisspeptin-54 and kisspeptin-10 are distinct research forms; findings about one formulation and study design cannot automatically be assigned to an online vial of the other.
Human evidence exists in monitored fertility research
In a 53-participant clinical study, kisspeptin-54 triggered egg maturation during IVF.[1] A later phase 2 open-label randomized dose-finding study in 60 women at high risk of ovarian hyperstimulation syndrome reported oocyte maturation and no moderate, severe, or critical OHSS in that study.[2]
These are promising specialist fertility findings, not proof of general fertility enhancement, testosterone optimization, libido treatment, anti-aging effects, or safe unsupervised use. They were conducted within tightly monitored IVF protocols and do not create a consumer dose.
Kisspeptin-10 has additional compounding concerns
FDA's compounding review identifies safety and immunogenicity concerns for kisspeptin-10 and notes that subcutaneous administration may pose significant risk.[3] That concern does not erase the kisspeptin-54 research, but it reinforces that isoform, formulation, route, manufacturing quality, and monitoring matter. No FDA-approved label defines contraindications, interactions, pregnancy use, or long-term repeated-use safety.
Compounded drugs are not FDA-approved or premarket-verified for safety, effectiveness, or quality.[4]
Regulatory status
Kisspeptin remains investigational in the United States; there is no FDA-approved kisspeptin product or prescribing label. Teloryx shows the human trials as research context only and does not publish a kisspeptin dose, cycle, or reconstitution recipe.